Effects of the use of phytosterol/-stanol-enriched margarines on adherence to statin therapy

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 12, 2010, Pages 1225-1232

  Eussen, Simone R B M ^a,b   De Jong, Nynke ^b   Rompelberg, Cathy J M ^b   Garssen, Johan ^a   Verschuren, W M Monique ^b   Klungel, Olaf H ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Adherence; Lipid lowering treatment; Phytosterols stanols; Statins

Indexed keywords

LIPID; MARGARINE; PHYTOSTEROL; PRESCRIPTION DRUG; STATIN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FAT INTAKE; FEMALE; FOOD FREQUENCY QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANK SUM TEST; RETROSPECTIVE STUDY;

AGED; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LONGITUDINAL STUDIES; MALE; MARGARINE; MEDICAL RECORD LINKAGE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHYTOSTEROLS; PROPORTIONAL HAZARDS MODELS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 78649511803     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2042     Document Type: Article

References (27)

1. Alevizos A, Mihas C, Mariolis A. Advertising campaigns of sterol-enriched food. An often neglected cause of reduced compliance to lipid lowering drug therapy. Cardiovasc Drugs Ther 2007; 21(2): 133-134.
2. Perreault S, Blais L, Dragomir A, et al. Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol 2005; 61(9): 667-674.
3. Dragomir A, Cote R, White M, et al. Relationship between adherence level to statins, clinical issues and health-care costs in real-life clinical setting. Value Health 2009; 13: 87-94.
4. Blair SN, Capuzzi DM, Gottlieb SO, Nguyen T, Morgan JM, Cater NB. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am J Cardiol 2000; 86(1): 46-52.
5. De Jong A, Plat J, Bast A, Godschalk RW, Basu S, Mensink RP. Effects of plant sterol and stanol ester consumption on lipid metabolism, antioxidant status and markers of oxidative stress, endothelial function and low-grade inflammation in patients on current statin treatment. Eur J Clin Nutr 2007; 62: 263-273.
6. Goldberg AC, Ostlund RE Jr, Bateman JH, Schimmoeller L, McPherson TB, Spilburg CA. Effect of plant stanol tablets on low-density lipoprotein cholesterol lowering in patients on statin drugs. Am J Cardiol 2006; 97(3): 376-379.
7. Ketomaki A, Gylling H, Miettinen TA. Non-cholesterol sterols in serum, lipoproteins, and red cells in statin-treated FH subjects off and on plant stanol and sterol ester spreads. Clin Chim Acta 2005; 353(1-2): 75-86.
8. Simons LA. Additive effect of plant sterol-ester margarine and cerivastatin in lowering low-density lipoprotein cholesterol in primary hypercholesterolemia. Am J Cardiol 2002; 90(7): 737-740.
9. De Jong N, Zuur A, Wolfs MC, Wendel-Vos GC, van Raaij JM, Schuit AJ. Exposure and effectiveness of phytosterol/-stanol-enriched margarines. Eur J Clin Nutr 2007; 61: 1407-1415.
10. Wolfs M, De Jong N, Ocke MC, Verhagen H, Monique Verschuren WM. Effectiveness of customary use of phytosterol/-stanol enriched margarines on blood cholesterol lowering. Food Chem Toxicol 2006; 44(10): 1682-1688.
11. Eussen S, Klungel O, Garssen J, et al. Support of drug therapy using functional foods and dietary supplements: focus on statin therapy. Br J Nutr 2010; 103(9): 1260-1277.
12. Verschuren WM, Blokstra A, Picavet HS, Smit HA. Cohort profile: the doetinchem cohort study. Int J Epidemiol 2008; 37(6): 1236-1241.
13. Herings RM, Bakker A, Stricker BH, Nap G. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health 1992; 46(2): 136-140.
14. PHARMO. Records Linkage System. Available at: [2 February 2010].
15. Hepburn P, Howlett J, Boeing H, et al. The application of post-market monitoring to novel foods. Food Chem Toxicol 2008; 46(1): 9-33.
16. Ocke MC, Bueno-de-Mesquita HB, Goddijn HE, et al. The dutch EPIC food frequency questionnaire. I. Description of the questionnaire, and relative validity and reproducibility for food groups. Int J Epidemiol 1997; 26 (Suppl 1): S37-S48.
17. Ocke MC, Bueno-de-Mesquita HB, Pols MA, Smit HA, van Staveren WA, Kromhout D. The dutch EPIC food frequency questionnaire. II. Relative validity and reproducibility for nutrients. Int J Epidemiol 1997; 26 (Suppl 1): S49-58.
18. WHO. WHO collaborating centre for drug statistics methodology, guidelines for ATC classification and DDD assignment. 2008. Available at:
19. Buurma H, Bouvy ML, De Smet PA, Floor-Schreudering A, Leufkens HG, Egberts AC. Prevalence and determinants of pharmacy shopping behaviour. J Clin Pharm Ther 2008; 33(1): 17-23.
20. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Refill persistence with chronic medication assessed from a pharmacy database was influenced by method of calculation. J Clin Epidemiol 2006; 59(1): 11-17.
21. Penning-van Beest FJ, Termorshuizen F, Goettsch WG, Klungel OH, Kastelein JJ, Herings RM. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2007; 28(2): 154-159.
22. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 1989; 79(3): 340-349.
23. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005; 23(11): 2101-2107.
24. Menckeberg TT, Belitser SV, Bouvy ML, et al. Distinguishing patterns in the dynamics of long-term medication use by Markov analysis: beyond persistence. BMC Health Services Res 2007; 7: 106.
25. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158(9): 915-920.
26. Chodick G, Shalev V, Gerber Y, et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 2008; 30(11): 2167-2179.
27. McClure DL, Valuck RJ, Glanz M, Hokanson JE. Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present. Pharmacoepidemiol Drug Saf 2007; 16(2): 132-143.